through glycan engineering.
Our mission
The next generation of therapeutics.
kyron.bio unlocks superior protein therapeutics by harnessing the power of glycan modifications.
Our novel engineering strategy precisely controls glycosylation patterns, opening a new era of antibody therapeutics.
This has the power to deliver better therapies and transform patient outcomes.
Read more about
Our people
are dedicated to revolutionising the way we make therapeutic drugs
TEAM
ADVISORS
Sabine Da Silva
EXECUTIVE ASSISTANT
BA West Chester University Pennsylvania
Prof. Michael Ferguson
HEAD DRUG DISCOVERY UNIVERSITY OF DUNDEE
Proudly supported by
We would love to hear from you
and leading angel investors.
News
kyron.bio wins the Servier Spartners Golden Ticket
Kyron.bio is honoured to be the recipient of the first Golden Ticket from Servier & Spartners BioLabs, providing a year of free lab space on the Servier site and access to key mentorship from the Servier team. We are delighted to be growing our company with the support of one of the most influential players in the French ecosystem!
Read more of
2024
Kyron.bio is proud to share that our CEO has been selected as a Women in Leadership Program by the European Innovation Council (EIC). This exceptional opportunity provides access to world-class mentorship, strategic leadership coaching, and a strong network of industry professionals, reinforcing our commitment to innovation and empowering women in leadership.
kyron.bio selected for EIC Women in Leadership Programme
2024
Kyron.bio is proud to win the the iLab ‘Concours d’innovation’ by Bpifrance, which focuses on supporting high-potential, innovative startups working on disruptive projects. kyron.bio is honoured to be among the 23% of women-led projects awarded this highly competitive grant, receiving €360K to support internal R&D and expedite the development of its cutting-edge glycan engineering strategy.
kyron.bio wins iLab concours d'innovation
2023